MedTrace Logo

Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)

NCT07425561 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-02-23

No results posted yet for this study

Summary

This is a single-center, non-profit observational study with two sequential phases: an initial retrospective phase followed by a prospective phase. Patients were enrolled during two consecutive, non-overlapping periods.

The primary objective of the study is to derive a clinical predictive score for multidrug-resistant (MDR) pathogen-related pneumonia in patients diagnosed with pneumonia presenting to the Emergency Department and/or admitted to the hospital from the community.

Conditions

  • Pneumonia
  • Pneumonia - Bacterial
  • Multi Drug Resistant
  • Multi Drug Resistant Organisms
  • Emergency
  • Community Acquired Pneumonia
  • Community Acquired Pneumonia (CAP)
  • Community Acquired Pneumonia, Severe

Interventions

OTHER

RESPIRE score

RESPIRE is a clinical risk prediction score developed to estimate the probability of pneumonia caused by multidrug-resistant (MDR) pathogens. In this observational study, the RESPIR-E score is derived and validated using routinely collected clinical and microbiological data. The score is not applied to guide clinical decision-making and does not influence diagnostic or therapeutic management. It is evaluated solely for observational and research purposes.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Careggi

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2026-02-01
Completion
2026-02-08

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07425561 on ClinicalTrials.gov